03/01/2024
9:04 AM | Bellerophon Therapeutics (Subject)
Nelson Michael Aaron (Filed by)
| Form SCHEDULE 13G | |
02/12/2024
2:44 PM | Bellerophon Therapeutics (Filer)
| Form DEFA14A | |
02/12/2024
11:39 AM | Bellerophon Therapeutics (Filer)
| Form DEFA14A | |
01/30/2024
8:29 AM | Bellerophon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/22/2024
2:21 PM | Bellerophon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/03/2024
12:49 PM | Bellerophon Therapeutics (Filer)
| Form DEFA14A | |
12/27/2023
8:01 AM | Bellerophon Therapeutics (Subject)
Nasdaq Stock Market LLC (Filed by)
| Form 25-NSE | |
|
12/12/2023
3:10 PM | Bellerophon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/21/2023
3:05 PM | Bellerophon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/14/2023
3:31 PM | Bellerophon Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/06/2023
3:30 PM | Bellerophon Therapeutics (Filer)
| Form DEF 14A | |
10/27/2023
9:50 AM | Bellerophon Therapeutics (Filer)
| Form PRE 14A | |
10/17/2023
8:05 PM | Bellerophon Therapeutics (Subject)
Puissance Life Science Opportunities Fund VI (Filed by)
| Form SC 13D/A | |
10/16/2023
7:56 PM | Bellerophon Therapeutics (Subject)
Puissance Life Science Opportunities Fund VI (Filed by)
| Form SC 13D/A | |
10/16/2023
7:51 PM | Bellerophon Therapeutics (Issuer)
Puissance Capital Fund LLC (0001695347) (Reporting)
Puissance Capital Management LP (Reporting)
Puissance Life Science Opportunities Fund VI (Reporting)
Wang Theodore T (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/16/2023
12:54 PM | Bellerophon Therapeutics (Filer)
| Form S-8 POS | |
10/16/2023
12:55 PM | Bellerophon Therapeutics (Filer)
| Form S-8 POS | |
10/16/2023
12:56 PM | Bellerophon Therapeutics (Filer)
| Form S-8 POS | |
10/16/2023
12:56 PM | Bellerophon Therapeutics (Filer)
| Form S-8 POS | |
10/16/2023
12:57 PM | Bellerophon Therapeutics (Filer)
| Form S-8 POS | |
10/16/2023
12:58 PM | Bellerophon Therapeutics (Filer)
| Form S-8 POS | |
10/16/2023
12:58 PM | Bellerophon Therapeutics (Filer)
| Form S-8 POS | |
10/16/2023
12:59 PM | Bellerophon Therapeutics (Filer)
| Form S-8 POS | |
10/16/2023
12:59 PM | Bellerophon Therapeutics (Filer)
| Form RW | |
10/13/2023
9:30 AM | Bellerophon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/13/2023
7:45 AM | Bellerophon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/24/2023
3:10 PM | Bellerophon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/14/2023
3:05 PM | Bellerophon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/11/2023
11:15 PM | Bellerophon Therapeutics (Filer)
| Form EFFECT | |
06/09/2023
12:03 PM | Bellerophon Therapeutics (Subject)
JANUS HENDERSON GROUP PLC (Filed by)
| Form SC 13G/A | |
06/07/2023
8:44 PM | Bellerophon Therapeutics (Subject)
Puissance Life Science Opportunities Fund VI (Filed by)
| Form SC 13D/A | |
06/07/2023
7:57 PM | Bellerophon Therapeutics (Subject)
Puissance Life Science Opportunities Fund VI (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/07/2023
8:21 PM | Bellerophon Therapeutics (Issuer)
Puissance Capital Fund LLC (0001695347) (Reporting)
Puissance Capital Management LP (Reporting)
Puissance Life Science Opportunities Fund VI (Reporting)
Wang Theodore T (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/07/2023
4:06 PM | Bellerophon Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
06/05/2023
7:08 AM | Bellerophon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/02/2023
7:55 AM | Bellerophon Therapeutics (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
05/31/2023
3:40 PM | Bellerophon Therapeutics (Filer)
| Form 424B5 | |
05/26/2023
3:41 PM | Bellerophon Therapeutics (Subject)
JANUS HENDERSON GROUP PLC (Filed by)
| Form SC 13G/A | |
05/25/2023
10:17 AM | Bellerophon Therapeutics (Subject)
JANUS HENDERSON GROUP PLC (Filed by)
| Form SC 13G | |
05/22/2023
5:51 PM | Bellerophon Therapeutics (Issuer)
Kim Bobae (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/22/2023
6:04 AM | Bellerophon Therapeutics (Subject)
Puissance Life Science Opportunities Fund VI (Filed by)
| Form SC 13D/A | |
Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad) 4x Better than Bitcoin
Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December. Get the name of the stock here >>> |
05/19/2023
7:55 PM | Bellerophon Therapeutics (Issuer)
Puissance Capital Fund LLC (0001695347) (Reporting)
Puissance Capital Management LP (Reporting)
Puissance Life Science Opportunities Fund VI (Reporting)
Wang Theodore T (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/18/2023
7:50 PM | Bellerophon Therapeutics (Subject)
Puissance Life Science Opportunities Fund VI (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/11/2023
7:30 AM | Bellerophon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/28/2023
7:38 AM | Bellerophon Therapeutics (Filer)
| Form ARS | |
04/28/2023
7:32 AM | Bellerophon Therapeutics (Filer)
| Form DEF 14A | |
04/28/2023
7:34 AM | Bellerophon Therapeutics (Filer)
| Form DEFA14A | |
